Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P07204

UPID:
TRBM_HUMAN

ALTERNATIVE NAMES:
Fetomodulin

ALTERNATIVE UPACC:
P07204; Q8IV29; Q9UC32

BACKGROUND:
Thrombomodulin, with its alternative name Fetomodulin, serves as a specific receptor on endothelial cells, forming a complex with thrombin. This interaction is essential for the activation of protein C, a process that significantly influences the coagulation pathway by limiting thrombin production and the activation of coagulation factors Va and VIIIa.

THERAPEUTIC SIGNIFICANCE:
The involvement of Thrombomodulin in conditions such as Thrombophilia and atypical Hemolytic uremic syndrome highlights its therapeutic relevance. Understanding the role of Thrombomodulin could open doors to potential therapeutic strategies, offering hope for patients suffering from these serious conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.